Palatin Technologies Inc. is a distinguished biopharmaceutical company that specializes in the development of targeted receptor-specific therapeutics aimed at treating numerous diseases within the United States. The firm's eminent product, Vyleesi, is a melanocortin receptor (MCr) agonist that serves to alleviate the symptoms of premenopausal women suffering from hypoactive sexual desire disorder. Additionally, Palatin Technologies has been developing oral PL8177, a selective MC1r agonist peptide that has already completed its Phase I clinical trial for the treatment of inflammatory bowel diseases. The company is also engaged in the production of PL9643, a peptide melanocortin agonist that actively targets multiple MCrs, including MC1r and MC5r, sought in treating anti-inflammatory ocular ailments such as dry eye disease, as well as melanocortin peptides intended for the treatment of diabetic retinopathy. To that end, it is working towards the development of PL3994, a peptide mimetic molecule with a structure mirroring that of amino acids, with the potential of treating an array of ailments. Additionally, the company is manufacturing L8177, an oral peptide formulation that effectively targets ulcerative colitis, leading to its entry into Phase 2 clinical trials. Established in 1986 and headquartered in Cranbury, New Jersey, Palatin Technologies Inc.'s dedication towards the research and development of therapeutic products has been unswerving.
Palatin's ticker is PTN
The company's shares trade on the AMEX stock exchange
They are based in Cranbury, New Jersey
There are 51-200 employees working at Palatin
It is palatin.com/about-us
Palatin is in the Healthcare sector
Palatin is in the Diagnostic Substances industry
The following five companies are Palatin's industry peers: